Zymeworks (ZYME)
(Delayed Data from NSDQ)
$8.33 USD
+0.07 (0.85%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $8.31 -0.02 (-0.24%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
ZYME 8.33 +0.07(0.85%)
Will ZYME be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ZYME
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
Other News for ZYME
Jazz Pharmaceuticals: Cheap But Complicated
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
ZYME Crosses Below Key Moving Average Level
Maintaining Hold on Zymeworks: ZW191’s Potential Amidst Competitive and Regulatory Hurdles
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024